Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats.
Identifieur interne : 003888 ( Ncbi/Merge ); précédent : 003887; suivant : 003889Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats.
Auteurs : Marco Malavolta [Italie] ; Robertina Giacconi [Italie] ; Dario Brunetti [Italie] ; Mauro Provinciali [Italie] ; Fabrizio Maggi [Italie]Source :
- Cells [ 2073-4409 ] ; 2020.
Descripteurs français
- KwdFr :
- Anti-infectieux (normes), Anti-infectieux (usage thérapeutique), Azithromycine (usage thérapeutique), Humains, Infections à coronavirus (immunologie), Infections à coronavirus (traitement médicamenteux), Interleukine-6 (immunologie), Pandémies, Pneumopathie virale (immunologie), Pneumopathie virale (traitement médicamenteux), Pyrazoles (usage thérapeutique), Santé mondiale (tendances), Vieillissement (immunologie).
- MESH :
- immunologie : Infections à coronavirus, Interleukine-6, Pneumopathie virale, Vieillissement.
- normes : Anti-infectieux.
- tendances : Santé mondiale.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Anti-infectieux, Azithromycine, Pyrazoles.
- Humains, Pandémies.
English descriptors
- KwdEn :
- Aging (immunology), Anti-Infective Agents (standards), Anti-Infective Agents (therapeutic use), Azithromycin (therapeutic use), Cellular Senescence (immunology), Coronavirus Infections (drug therapy), Coronavirus Infections (immunology), Global Health (trends), Humans, Interleukin-6 (immunology), Pandemics, Pneumonia, Viral (drug therapy), Pneumonia, Viral (immunology), Pyrazoles (therapeutic use).
- MESH :
- chemical , immunology : Interleukin-6.
- chemical , standards : Anti-Infective Agents.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- immunology : Aging, Cellular Senescence, Coronavirus Infections, Pneumonia, Viral.
- chemical , therapeutic use : Anti-Infective Agents, Azithromycin, Pyrazoles.
- trends : Global Health.
- Humans, Pandemics.
Abstract
The higher death rate caused by COVID-19 in older people, especially those with comorbidities, is a challenge for biomedical aging research. Here we explore the idea that an exacerbated inflammatory response, in particular that mediated by IL-6, may drive the deleterious consequences of the infection. Data shows that other RNA viruses, such as influenza virus, can display enhanced replication efficiency in senescent cells, suggesting that the accumulation of senescent cells with aging and age-related diseases may play a role in this phenomenon. However, at present, we are completely unaware of the response to SARS-CoV and SARS-COV-2 occurring in senescent cells. We deem that this is a priority area of research because it could lead to the development of several therapeutic strategies based on senotherapeutics or prevent unsuccessful attempts. Two of these senotherapeutics, azithromycin and ruxolitinib, are currently undergoing testing for their efficacy in treating COVID-19. The potential of these strategies is not only for ameliorating the consequences of the current emergence of SARS-CoV-2, but also for the future emergence of new viruses or mutated ones for which we are completely unprepared and for which no vaccines are available.
DOI: 10.3390/cells9040909
PubMed: 32276453
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000227
- to stream PubMed, to step Curation: 000227
- to stream PubMed, to step Checkpoint: 000514
Links to Exploration step
pubmed:32276453Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats.</title><author><name sortKey="Malavolta, Marco" sort="Malavolta, Marco" uniqKey="Malavolta M" first="Marco" last="Malavolta">Marco Malavolta</name><affiliation wicri:level="1"><nlm:affiliation>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona</wicri:regionArea><wicri:noRegion>60121 Ancona</wicri:noRegion></affiliation></author><author><name sortKey="Giacconi, Robertina" sort="Giacconi, Robertina" uniqKey="Giacconi R" first="Robertina" last="Giacconi">Robertina Giacconi</name><affiliation wicri:level="1"><nlm:affiliation>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona</wicri:regionArea><wicri:noRegion>60121 Ancona</wicri:noRegion></affiliation></author><author><name sortKey="Brunetti, Dario" sort="Brunetti, Dario" uniqKey="Brunetti D" first="Dario" last="Brunetti">Dario Brunetti</name><affiliation wicri:level="1"><nlm:affiliation>Mitochondrial Medicine Laboratory, Department of Medical Biotechnology and Translational Medicine, University of Milan, 20133 Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Mitochondrial Medicine Laboratory, Department of Medical Biotechnology and Translational Medicine, University of Milan, 20133 Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Provinciali, Mauro" sort="Provinciali, Mauro" uniqKey="Provinciali M" first="Mauro" last="Provinciali">Mauro Provinciali</name><affiliation wicri:level="1"><nlm:affiliation>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona</wicri:regionArea><wicri:noRegion>60121 Ancona</wicri:noRegion></affiliation></author><author><name sortKey="Maggi, Fabrizio" sort="Maggi, Fabrizio" uniqKey="Maggi F" first="Fabrizio" last="Maggi">Fabrizio Maggi</name><affiliation wicri:level="4"><nlm:affiliation>Department of Translational Research, University of Pisa, 56126 Pisa, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Translational Research, University of Pisa, 56126 Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region nuts="2">Toscane</region></placeName><orgName type="university">Université de Pise</orgName><placeName><settlement type="city">Pise</settlement><region type="region" nuts="2">Toscane</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32276453</idno><idno type="pmid">32276453</idno><idno type="doi">10.3390/cells9040909</idno><idno type="wicri:Area/PubMed/Corpus">000227</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000227</idno><idno type="wicri:Area/PubMed/Curation">000227</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000227</idno><idno type="wicri:Area/PubMed/Checkpoint">000514</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000514</idno><idno type="wicri:Area/Ncbi/Merge">003888</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats.</title><author><name sortKey="Malavolta, Marco" sort="Malavolta, Marco" uniqKey="Malavolta M" first="Marco" last="Malavolta">Marco Malavolta</name><affiliation wicri:level="1"><nlm:affiliation>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona</wicri:regionArea><wicri:noRegion>60121 Ancona</wicri:noRegion></affiliation></author><author><name sortKey="Giacconi, Robertina" sort="Giacconi, Robertina" uniqKey="Giacconi R" first="Robertina" last="Giacconi">Robertina Giacconi</name><affiliation wicri:level="1"><nlm:affiliation>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona</wicri:regionArea><wicri:noRegion>60121 Ancona</wicri:noRegion></affiliation></author><author><name sortKey="Brunetti, Dario" sort="Brunetti, Dario" uniqKey="Brunetti D" first="Dario" last="Brunetti">Dario Brunetti</name><affiliation wicri:level="1"><nlm:affiliation>Mitochondrial Medicine Laboratory, Department of Medical Biotechnology and Translational Medicine, University of Milan, 20133 Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Mitochondrial Medicine Laboratory, Department of Medical Biotechnology and Translational Medicine, University of Milan, 20133 Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Provinciali, Mauro" sort="Provinciali, Mauro" uniqKey="Provinciali M" first="Mauro" last="Provinciali">Mauro Provinciali</name><affiliation wicri:level="1"><nlm:affiliation>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona</wicri:regionArea><wicri:noRegion>60121 Ancona</wicri:noRegion></affiliation></author><author><name sortKey="Maggi, Fabrizio" sort="Maggi, Fabrizio" uniqKey="Maggi F" first="Fabrizio" last="Maggi">Fabrizio Maggi</name><affiliation wicri:level="4"><nlm:affiliation>Department of Translational Research, University of Pisa, 56126 Pisa, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Translational Research, University of Pisa, 56126 Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region nuts="2">Toscane</region></placeName><orgName type="university">Université de Pise</orgName><placeName><settlement type="city">Pise</settlement><region type="region" nuts="2">Toscane</region></placeName></affiliation></author></analytic><series><title level="j">Cells</title><idno type="eISSN">2073-4409</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aging (immunology)</term><term>Anti-Infective Agents (standards)</term><term>Anti-Infective Agents (therapeutic use)</term><term>Azithromycin (therapeutic use)</term><term>Cellular Senescence (immunology)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (immunology)</term><term>Global Health (trends)</term><term>Humans</term><term>Interleukin-6 (immunology)</term><term>Pandemics</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (immunology)</term><term>Pyrazoles (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anti-infectieux (normes)</term><term>Anti-infectieux (usage thérapeutique)</term><term>Azithromycine (usage thérapeutique)</term><term>Humains</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Interleukine-6 (immunologie)</term><term>Pandémies</term><term>Pneumopathie virale (immunologie)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pyrazoles (usage thérapeutique)</term><term>Santé mondiale (tendances)</term><term>Vieillissement (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Interleukin-6</term></keywords><keywords scheme="MESH" type="chemical" qualifier="standards" xml:lang="en"><term>Anti-Infective Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Interleukine-6</term><term>Pneumopathie virale</term><term>Vieillissement</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Aging</term><term>Cellular Senescence</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Anti-infectieux</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Santé mondiale</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Infective Agents</term><term>Azithromycin</term><term>Pyrazoles</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Global Health</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-infectieux</term><term>Azithromycine</term><term>Pyrazoles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The higher death rate caused by COVID-19 in older people, especially those with comorbidities, is a challenge for biomedical aging research. Here we explore the idea that an exacerbated inflammatory response, in particular that mediated by IL-6, may drive the deleterious consequences of the infection. Data shows that other RNA viruses, such as influenza virus, can display enhanced replication efficiency in senescent cells, suggesting that the accumulation of senescent cells with aging and age-related diseases may play a role in this phenomenon. However, at present, we are completely unaware of the response to SARS-CoV and SARS-COV-2 occurring in senescent cells. We deem that this is a priority area of research because it could lead to the development of several therapeutic strategies based on senotherapeutics or prevent unsuccessful attempts. Two of these senotherapeutics, azithromycin and ruxolitinib, are currently undergoing testing for their efficacy in treating COVID-19. The potential of these strategies is not only for ameliorating the consequences of the current emergence of SARS-CoV-2, but also for the future emergence of new viruses or mutated ones for which we are completely unprepared and for which no vaccines are available.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32276453</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>04</Month><Day>08</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">E909</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells9040909</ELocationID><Abstract><AbstractText>The higher death rate caused by COVID-19 in older people, especially those with comorbidities, is a challenge for biomedical aging research. Here we explore the idea that an exacerbated inflammatory response, in particular that mediated by IL-6, may drive the deleterious consequences of the infection. Data shows that other RNA viruses, such as influenza virus, can display enhanced replication efficiency in senescent cells, suggesting that the accumulation of senescent cells with aging and age-related diseases may play a role in this phenomenon. However, at present, we are completely unaware of the response to SARS-CoV and SARS-COV-2 occurring in senescent cells. We deem that this is a priority area of research because it could lead to the development of several therapeutic strategies based on senotherapeutics or prevent unsuccessful attempts. Two of these senotherapeutics, azithromycin and ruxolitinib, are currently undergoing testing for their efficacy in treating COVID-19. The potential of these strategies is not only for ameliorating the consequences of the current emergence of SARS-CoV-2, but also for the future emergence of new viruses or mutated ones for which we are completely unprepared and for which no vaccines are available.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malavolta</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8442-1763</Identifier><AffiliationInfo><Affiliation>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giacconi</LastName><ForeName>Robertina</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1468-2140</Identifier><AffiliationInfo><Affiliation>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunetti</LastName><ForeName>Dario</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2740-9370</Identifier><AffiliationInfo><Affiliation>Mitochondrial Medicine Laboratory, Department of Medical Biotechnology and Translational Medicine, University of Milan, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Provinciali</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0568-3002</Identifier><AffiliationInfo><Affiliation>Advanced Technology Center for Aging Research, IRCCS INRCA, 60121 Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maggi</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7489-5271</Identifier><AffiliationInfo><Affiliation>Department of Translational Research, University of Pisa, 56126 Pisa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Ricerca Corrente</GrantID><Agency>Ministero della Salute</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C540383">INCB018424</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016922" MajorTopicYN="N">Cellular Senescence</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">SASP inhibitors</Keyword><Keyword MajorTopicYN="Y">cellular senescence</Keyword><Keyword MajorTopicYN="Y">extracellular vesicles</Keyword><Keyword MajorTopicYN="Y">inflammation</Keyword><Keyword MajorTopicYN="Y">mitochondria</Keyword><Keyword MajorTopicYN="Y">senolytics</Keyword><Keyword MajorTopicYN="Y">senoptotics</Keyword><Keyword MajorTopicYN="Y">viral infection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32276453</ArticleId><ArticleId IdType="pii">cells9040909</ArticleId><ArticleId IdType="doi">10.3390/cells9040909</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country><region><li>Lombardie</li><li>Toscane</li></region><settlement><li>Milan</li><li>Pise</li></settlement><orgName><li>Université de Pise</li></orgName></list><tree><country name="Italie"><noRegion><name sortKey="Malavolta, Marco" sort="Malavolta, Marco" uniqKey="Malavolta M" first="Marco" last="Malavolta">Marco Malavolta</name></noRegion><name sortKey="Brunetti, Dario" sort="Brunetti, Dario" uniqKey="Brunetti D" first="Dario" last="Brunetti">Dario Brunetti</name><name sortKey="Giacconi, Robertina" sort="Giacconi, Robertina" uniqKey="Giacconi R" first="Robertina" last="Giacconi">Robertina Giacconi</name><name sortKey="Maggi, Fabrizio" sort="Maggi, Fabrizio" uniqKey="Maggi F" first="Fabrizio" last="Maggi">Fabrizio Maggi</name><name sortKey="Provinciali, Mauro" sort="Provinciali, Mauro" uniqKey="Provinciali M" first="Mauro" last="Provinciali">Mauro Provinciali</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003888 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003888 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:32276453
|texte= Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:32276453" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |